PainRelief.com Interview with:
Leon S. Moskatel, MD
Clinical Assistant Professor
Division of Headache, Department of Neurology
Stanford University
Palo Alto, CA

PainRelief.com: What is the background for this study?

Response: OnabotulinumtoxinA (onabotA) is one of the most effective and well-tolerated treatments for chronic migraine, which the FDA approved for the prevention of chronic migraine in 2010.

OnabotA for chronic migraine is usually administered according to the PREEMPT protocol every 12 weeks for at least 3 treatments. Previous studies examining the long-term use of onabotA have been limited by either relatively short duration or small sample size. At the Stanford Headache Center, we were able to query our electronic medical records and create a prescription database to examine long-term persistence to onabotA over 11 years, between 2011-2021.

Last Updated on March 29, 2024 by PainRelief.com